Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MIGLITOL vs GLYSET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reversible competitive inhibitor of alpha-glucosidase in the intestinal brush border; delays glucose absorption and lowers postprandial hyperglycemia.
Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.
Type 2 diabetes mellitus as monotherapy or in combination with sulfonylureas, metformin, or insulin when diet and exercise do not provide adequate glycemic control
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
25 mg orally three times daily with the first bite of each main meal; may increase to 50 mg three times daily after 4-8 weeks, maximum 100 mg three times daily.
50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.
Plasma elimination half-life ≈ 2 hours; clinical effect (alpha-glucosidase inhibition) persists longer due to enzyme binding; half-life increases in renal impairment (creatinine clearance < 25 m L/min).
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function (creatinine clearance >60 m L/min). Clinical context: No accumulation occurs with twice-daily dosing in normal renal function; half-life is prolonged in renal impairment (up to 18 hours in end-stage renal disease).
Not metabolized; excreted unchanged in feces (via enzymatic breakdown in gut lumen) and urine (minor).
Not metabolized; excreted unchanged primarily in feces (51% as unchanged drug, 35% as metabolites) and urine (2-5% as unchanged drug).
Primarily excreted unchanged in urine (≈ 65%) via glomerular filtration; remainder recovered as metabolites in urine (25%) and feces (5%); total recovery in urine and feces ≈ 95% within 24 hours.
Primarily excreted unchanged in the urine (renal elimination accounts for >95% of absorbed dose). Fecal elimination is negligible (<2%).
Negligible (< 4%), primarily bound to albumin.
Protein binding is very low (approximately 5-10%), primarily to albumin, with no significant binding to other plasma proteins.
Approximately 0.18 L/kg; distributes mainly in extracellular fluid with limited tissue penetration.
Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution mainly in extracellular fluid and minimal tissue binding.
Low and variable oral bioavailability: approximately 50% (range 35–65%) due to incomplete absorption and intestinal metabolism; dose proportional for doses up to 100 mg.
Oral bioavailability is <2% for the parent compound due to extensive metabolism by intestinal bacteria; however, the active metabolite (miglitol-like) has high local activity. Systemic absorption is minimal (1-2%), consistent with its site of action in the gut.
GFR <25 m L/min/1.73m2: contraindicated. No adjustment needed for GFR ≥25 m L/min/1.73m2.
Contraindicated if GFR < 25 m L/min/1.73 m². No adjustment needed for GFR ≥ 25 m L/min/1.73 m².
No dose adjustment required for hepatic impairment; not studied in Child-Pugh C. Use with caution in severe hepatic disease.
No specific guidelines; use caution in Child-Pugh class B or C due to limited data.
Safety and efficacy not established in pediatric patients.
Not recommended for pediatric patients due to lack of safety and efficacy data.
No specific dose adjustment, but monitor renal function; elderly may have age-related decline in renal function. Use lowest effective dose.
Initiate at lowest dose (50 mg three times daily); titrate cautiously due to age-related renal decline.
None.
None
Hypoglycemia risk when used with insulin or sulfonylureas,Hepatotoxicity (rare, monitor liver enzymes),Gastrointestinal side effects (flatulence, diarrhea, abdominal pain) due to undigested carbohydrates in colon
Hypoglycemia when used in combination with sulfonylureas or insulin (must be treated with glucose, not sucrose),Gastrointestinal adverse effects (abdominal pain, diarrhea, flatulence) due to undigested carbohydrates fermenting in the colon,Hepatotoxicity (rare, monitor liver enzymes),May cause loss of glycemic control if used with intestinal disorders
Diabetic ketoacidosis,Inflammatory bowel disease,Colonic ulceration,Intestinal obstruction or predisposition to obstruction,Chronic intestinal diseases associated with malabsorption,Hypersensitivity to miglitol
Diabetic ketoacidosis,Inflammatory bowel disease,Colonic ulceration,Partial intestinal obstruction,Predisposition to intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Cirrhosis,Hypersensitivity to miglitol
Carbohydrates in the meal may cause increased flatulence and diarrhea. Sucrose and table sugar are not effective for treating hypoglycemia; use pure glucose. Avoid excessive simple carbohydrates if tolerated.
Avoid high-sucrose or fructose-containing foods and drinks as GLYSET inhibits the digestion of sucrose, leading to increased fermentation and gastrointestinal distress. Complex carbohydrates (starches) are affected; simple sugars like glucose are not.
No adequate well-controlled studies in pregnant women. Animal studies show no evidence of fetal harm at doses up to 150 mg/kg in rats and 75 mg/kg in rabbits. Risk cannot be ruled out; use only if clearly needed.
Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed.
No data on presence in human milk. M/P ratio unknown. Consider benefit of breastfeeding versus potential risk to infant.
Excreted in human milk; M/P ratio unknown. Caution in nursing mothers due to potential for GI effects in infants.
No pharmacokinetic studies in pregnancy; dosing adjustments not established. Monitor glycemic control closely and adjust as needed per clinical response.
No dose adjustment recommended based on pharmacokinetic data; monitor glycemic control closely and adjust as needed.
Miglitol is an alpha-glucosidase inhibitor that delays carbohydrate absorption. It is not effective for type 1 diabetes. Monitor liver enzymes; cases of hepatitis have been reported. Do not use in patients with inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction. Hypoglycemia must be treated with oral glucose (dextrose), not sucrose because sucrase is inhibited. Take with the first bite of each main meal.
GLYSET (miglitol) is an alpha-glucosidase inhibitor that delays carbohydrate digestion, reducing postprandial hyperglycemia. It is not effective for fasting hyperglycemia and should not be used as monotherapy for type 1 diabetes or DKA. Monitor liver function tests; rare hepatotoxicity reported. Avoid in patients with inflammatory bowel disease or intestinal obstruction.
Take miglitol three times daily at the start of each main meal (with the first bite).,If you miss a dose, skip it if the meal is already finished; do not double the dose.,Common side effects include flatulence, diarrhea, and abdominal pain; these may decrease over time.,If hypoglycemia occurs, use glucose tablets or gel; table sugar (sucrose) will not work.,Inform your doctor if you have a history of kidney disease, inflammatory bowel disease, or intestinal obstruction.
Take with the first bite of each main meal to delay carbohydrate absorption.,Common side effects include flatulence, diarrhea, and abdominal discomfort, which often improve over time.,If hypoglycemia occurs, use glucose tablets or milk, not sucrose or fruit juice, as GLYSET prevents sucrose breakdown.,Monitor blood glucose regularly, especially when starting or changing dose.,Do not skip meals; take medication exactly as prescribed.
"Miglitol, an alpha-glucosidase inhibitor, delays carbohydrate digestion and absorption, reducing postprandial hyperglycemia. Stanozolol, an anabolic steroid, can increase insulin sensitivity and enhance glucose utilization, potentially leading to additive hypoglycemic effects. Concurrent use may result in unexpectedly low blood glucose levels, especially in diabetic patients on insulin or sulfonylureas."
"Miglitol, an alpha-glucosidase inhibitor, delays carbohydrate absorption and reduces postprandial hyperglycemia. Levomilnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may enhance insulin sensitivity or alter glucose metabolism, potentially increasing the hypoglycemic effect when combined with miglitol. This interaction could result in additive blood glucose lowering and an elevated risk of hypoglycemic episodes, particularly in diabetic patients."
"Saquinavir, a protease inhibitor used in HIV therapy, may decrease the therapeutic efficacy of miglitol, an alpha-glucosidase inhibitor for type 2 diabetes, by potentially increasing gastrointestinal motility or altering gut enzyme activity. This interaction can lead to reduced miglitol absorption and diminished postprandial glycemic control, increasing the risk of hyperglycemia in diabetic patients. Clinical outcomes include elevated blood glucose levels and potential loss of diabetes management."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MIGLITOL vs GLYSET, answered by our medical review team.
MIGLITOL is a Alpha-Glucosidase Inhibitor that works by Reversible competitive inhibitor of alpha-glucosidase in the intestinal brush border; delays glucose absorption and lowers postprandial hyperglycemia.. GLYSET is a Alpha-Glucosidase Inhibitor Antidiabetic that works by Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MIGLITOL and GLYSET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MIGLITOL is: 25 mg orally three times daily with the first bite of each main meal; may increase to 50 mg three times daily after 4-8 weeks, maximum 100 mg three times daily.. The standard adult dose of GLYSET is: 50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MIGLITOL and GLYSET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MIGLITOL is classified as Category A/B. No adequate well-controlled studies in pregnant women. Animal studies show no evidence of fetal harm at doses up to 150 mg/kg in rats and 75 mg/kg in rabbits. Risk cannot be ruled . GLYSET is classified as Category C. Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.